Innovative combination Finasteride + Tadalafil

Innovative combination Finasteride + Tadalafil
Product Description

Innovative combination Finasteride + Tadalafil  

  • Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe. 
  • The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of therapeutic effect and reduction of finasteride-induced adverse events (e.g. erectile dysfunction) 
  • Co-administration of Tadalafil 5 mg and finasteride 5 mg is recommended by European association of Urology (EAU – Guideline for Management of Non-neurogenic Male LUTS)  and approved by FDA for BPH for up to 26 weeks 
  • For more details contact Vaibhav Sharma, Head of Value added products ([email protected] )

Zentiva

  • CZ
  • 2019
    On CPHI since

Zentiva

  • CZ
  • 2019
    On CPHI since

More Products from Zentiva (4)

  • Zent2U - Zentiva B2B Platform

    Product Zent2U - Zentiva B2B Platform

    Zent2U (www.zent2u.com) is a B2B platform of Zentiva established in 2019 to collaborate with customers on:

    - Licensing-out dossiers developed by Zentiva

    - Co-development opportunities by co-financing Zentiva's products in development

    - CMO services by Zentiva in production ...
  • Value Added Dasatinib

    Product Value Added Dasatinib

    Value added Dasatinib (Teaser attached)  •  Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)  •  Current available products on the market are not completely absorbed by those patients ...
  • Value Added Abiraterone

    Product Value Added Abiraterone

    Value added Abiraterone  •  Abiraterone is a medication used to treat prostate cancer  •  The recommended dose is 1,000 mg as a single daily dose that must not be taken with food.  •  Administering  with food results up to a 10-fold (AUC) and up to a 17-fo...
  • CDMO

    Product CDMO

    Services.

Zentiva resources (7)